Literature DB >> 12503076

DNA repair gene O6-methylguanine-DNA methyltransferase: promoter hypermethylation associated with decreased expression and G:C to A:T mutations of p53 in brain tumors.

Dong Yin1, Dong Xie, Wolf-Karsten Hofmann, Wenxuan Zhang, Kamlesh Asotra, Rex Wong, Keith L Black, H Phillip Koeffler.   

Abstract

The DNA repair enzyme O(6)-methylguanine-DNA methyltransferase (MGMT) removes alkylating adducts from the O(6) position of guanine and protects cells from cytotoxic and mutagenic effects. Expression of MGMT is decreased in some cancers, which may be the result of methylation of CpG islands of both the promoter and coding regions of the gene. We studied the methylation status of the MGMT promoter in a very large collection of brain tumors (85) using methylation-specific polymerase chain reaction (PCR). Aberrant methylation occurred in 48% of 85 human brain tumor samples. Quantitative real-time PCR showed that expression of MGMT mRNA levels was significantly decreased (P < 0.001) in those brain tumors that had methylation of the promoter region of their MGMT gene. MGMT can prevent G to A mutations by removing alkyl groups from the O(6) position of guanine. We found a significantly increased frequency of G:C to A:T mutations of the p53 gene in brain tumors having a methylated MGMT promoter compared with those having an unmethylated MGMT promoter (P < 0.05), and all the non-CpG dinucleotide G:C to A:T mutations of p53 were in samples with a methylated MGMT promoter. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12503076     DOI: 10.1002/mc.10094

Source DB:  PubMed          Journal:  Mol Carcinog        ISSN: 0899-1987            Impact factor:   4.784


  13 in total

1.  Loss of O6-methylguanine-DNA methyltransferase protein expression is a favorable prognostic marker in diffuse large B-cell lymphoma.

Authors:  Toshihito Ohno; Junji Hiraga; Haruhiko Ohashi; Chiho Sugisaki; Eika Li; Haruhiko Asano; Tastuya Ito; Hirokazu Nagai; Yoriko Yamashita; Naoyoshi Mori; Tomohiro Kinoshita; Tomoki Naoe
Journal:  Int J Hematol       Date:  2006-05       Impact factor: 2.490

2.  Completeness of required site-specific factors for brain and CNS tumors in the Surveillance, Epidemiology and End Results (SEER) 18 database (2004-2012, varying).

Authors:  Quinn T Ostrom; Haley Gittleman; Carol Kruchko; David N Louis; Daniel J Brat; Mark R Gilbert; Valentina I Petkov; Jill S Barnholtz-Sloan
Journal:  J Neurooncol       Date:  2016-07-14       Impact factor: 4.130

3.  Promoter hypermethylation of the DNA-repair gene O6-methylguanine-DNA methyltransferase and p53 mutation in diffuse large B-cell lymphoma.

Authors:  Junji Hiraga; Tomohiro Kinoshita; Toshihito Ohno; Naoyoshi Mori; Haruhiko Ohashi; Shouko Fukami; Atsuhiko Noda; Atsushi Ichikawa; Tomoki Naoe
Journal:  Int J Hematol       Date:  2006-10       Impact factor: 2.490

4.  Immunohistochemical study for O6-methylguanine-DNA methyltransferase in the non-neoplastic and neoplastic components of gliomas.

Authors:  Satoshi Nakasu; Tadateru Fukami; Kazumi Baba; Masayuki Matsuda
Journal:  J Neurooncol       Date:  2004-12       Impact factor: 4.130

5.  The A/G allele of rs16906252 predicts for MGMT methylation and is selectively silenced in premalignant lesions from smokers and in lung adenocarcinomas.

Authors:  Shuguang Leng; Amanda M Bernauer; Chibo Hong; Kieu C Do; Christin M Yingling; Kristina G Flores; Mathewos Tessema; Carmen S Tellez; Randall P Willink; Elizabeth A Burki; Maria A Picchi; Christine A Stidley; Michael D Prados; Joseph F Costello; Frank D Gilliland; Richard E Crowell; Steven A Belinsky
Journal:  Clin Cancer Res       Date:  2011-02-25       Impact factor: 12.531

6.  Implication of a Chromosome 15q15.2 Locus in Regulating UBR1 and Predisposing Smokers to MGMT Methylation in Lung.

Authors:  Shuguang Leng; Guodong Wu; Leonard B Collins; Cynthia L Thomas; Carmen S Tellez; Andrew R Jauregui; Maria A Picchi; Xiequn Zhang; Daniel E Juri; Dhimant Desai; Shantu G Amin; Richard E Crowell; Christine A Stidley; Yushi Liu; James A Swenberg; Yong Lin; Marc G Wathelet; Frank D Gilliland; Steven A Belinsky
Journal:  Cancer Res       Date:  2015-07-16       Impact factor: 12.701

7.  Disulfiram is a direct and potent inhibitor of human O6-methylguanine-DNA methyltransferase (MGMT) in brain tumor cells and mouse brain and markedly increases the alkylating DNA damage.

Authors:  Ameya Paranjpe; Ruiwen Zhang; Francis Ali-Osman; George C Bobustuc; Kalkunte S Srivenugopal
Journal:  Carcinogenesis       Date:  2013-11-05       Impact factor: 4.944

Review 8.  MGMT testing--the challenges for biomarker-based glioma treatment.

Authors:  Wolfgang Wick; Michael Weller; Martin van den Bent; Marc Sanson; Markus Weiler; Andreas von Deimling; Christoph Plass; Monika Hegi; Michael Platten; Guido Reifenberger
Journal:  Nat Rev Neurol       Date:  2014-06-10       Impact factor: 42.937

9.  Combination treatment with theranostic nanoparticles for glioblastoma sensitization to TMZ.

Authors:  Byunghee Yoo; Marytheresa A Ifediba; Subrata Ghosh; Zdravka Medarova; Anna Moore
Journal:  Mol Imaging Biol       Date:  2014-10       Impact factor: 3.488

10.  Silencing of MGMT expression by promoter hypermethylation in the metaplasia-dysplasia-carcinoma sequence of Barrett's esophagus.

Authors:  Doerthe Kuester; Wa'el El-Rifai; DunFa Peng; Petra Ruemmele; Ivonne Kroeckel; Brigitte Peters; Christopher A Moskaluk; Manfred Stolte; Klaus Mönkemüller; Frank Meyer; Hans-Ulrich Schulz; Arndt Hartmann; Albert Roessner; Regine Schneider-Stock
Journal:  Cancer Lett       Date:  2008-11-21       Impact factor: 8.679

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.